Amryt Pharma
Sustainability Report and Carbon Intensity Rankings
Is Amryt Pharma doing their part?
Their DitchCarbon score is 45
Amryt Pharma has a DitchCarbon Score of 45 out of 100, indicating a moderate level of sustainability in their operations. This score suggests that the company’s carbon intensity is relatively high, implying there is significant room for improvement in reducing emissions. Efforts to lower their carbon intensity would enhance their sustainability profile and contribute to better environmental performance.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Amryt Pharma is part of the industrial manufacturing sector, which has a carbon intensity ranking of very low. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Medium
High
Very high
Amryt Pharma is situated in Ireland, a country with a very low carbon intensity rating, indicating a cleaner energy grid. This favorable location contributes positively to the company’s sustainability efforts by reducing its carbon footprint.
Unlock 30+ emissions data points on Amryt Pharma
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Amryt Pharma
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
3.71%
...this company is doing 3.71% better in emissions than the industry average.
Amryt Pharma, founded in 2015 and headquartered in Dublin, operates within the pharmaceutical industry, specializing in treatments for rare and orphan diseases. The company offers innovative drugs like Lojuxta for Homozygous Familial Hypercholesterolemia and is advancing clinical trials for AP101, a potential therapy for Epidermolysis Bullosa. Amryt Pharma entered the public market in 2016 through a reverse takeover of Fastnet Equity PLC and continues to develop its portfolio, including AP102 for neuroendocrine diseases.
Bad news, Amryt Pharma hasn't committed to SBTi goals yet
Amryt Pharma has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company is still in the process of defining clear, science-based emissions reduction targets to align with global efforts to mitigate climate change.
Not participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.